Generate a tailored SOP for Dr. Diana Ranoa. Improve your application with a focused, well-structured draft.
The Ranoa lab aims to develop T cell receptor-based immunotherapy for solid tumors. Specifically, they intend to define chimeric antigen receptor (CAR)-T cell-mediated mutual reprogramming of tumor and host immune cells in the tumor microenvironment using syngeneic murine tumor models. The lab works to uncover the deep mechanistic understanding of the spatiotemporal molecular factors that define the pathways of resistance to CAR-T based therapies and determine the molecular mechanisms responsible for altering the functional states of host immune cells in tumors. They engineer CAR-T cells to overcome immune suppression in solid tumors, improve therapeutic efficacy in single-agent and combination treatment modalities, and reduce adverse side effects. Techniques include molecular biology assays, tissue culture work, animal models, and big data analyses. They handle human and murine tumor cell lines, perform genetic engineering, conduct animal experiments, and analyze bulk and single-cell RNA sequencing data.
GRE is optional for admission to all graduate programs in Statistics. Full status admission requires higher language scores than limited status.